Abstract

In this study, we examined the effect of ethanolic extract of Salicornia herbacea (ESH), isorhamnetin 3-O-glucoside (I3G), quercetin 3-O-glucoside (Q3G), quercetin, and isorhamnetin on α-glucosidase activity and glucose-stimulated insulin secretion (GSIS) in insulin-secreting rat insulinoma (INS-1) cells. A portion of the ethyl acetate fraction of ESH was chromatographed on a silica gel by a gradient elution with chloroform and methanol to provide Q3G and I3G. ESH, Q3G, and quercetin inhibited α-glucosidase activity, and quercetin (IC50 value was 29.47 ± 3.36 μM) inhibited the activity more effectively than Q3G. We further demonstrated that ESH, Q3G, quercetin, I3G, and isorhamnetin promote GSIS in INS-1 pancreatic β-cells without inducing cytotoxicity. Among them, I3G was the most effective in enhancing GSIS. I3G enhanced the phosphorylation of total extracellular signal-regulated kinase (ERK), insulin receptor substrate-2 (IRS-2), phosphatidylinositol 3-kinase (PI3K), Akt, and activated pancreatic and duodenal homeobox-1 (PDX-1), which are associated with insulin secretion and β-cell function. As components of ESH, Q3G has the potential to regulate blood glucose by inhibiting α-glucosidase activity, and I3G enhances the insulin secretion, but its bioavailability should be considered in determining biological importance.

Highlights

  • Diabetes mellitus (DM) is one of the most prevalent and costly health conditions impairing patients’ quality of life worldwide [1]

  • This study demonstrates that extract of Salicornia herbacea (ESH) has the potential to both inhibit α-glucosidase activity and increase insulin secretion

  • The structures of quercetin 3-O-glucoside (Q3G) and isorhamnetin 3-O-glucoside (I3G) were elucidated by spectral analysis and comparison with the published literature [23,24]

Read more

Summary

Introduction

Diabetes mellitus (DM) is one of the most prevalent and costly health conditions impairing patients’ quality of life worldwide [1]. Miglitol, acarbose, and voglibose are known to induce side effects such as stomach pain, diarrhea, and bloating, known as a side effect of any compound that blocks this enzyme [3]. Sulfonylureas such as glibenclamide and gliclazide are widely used for the treatment of type 2 DM. These sulfonylureas potentiate insulin secretion from pancreatic β-cells, but are currently being largely replaced by inhibitors of dipeptidyl peptidase-4 (DPP-4) and glucosurics [4]. Side effects such as skin reactions, nausea, and dizziness have been reported [5]

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call